Bryan Garnier & Co Virtual European Healthcare Conference
Date:November 17, 2020
Fireside Chat:November 17, 2020 at10:00 a.m. CET Jefferies Virtual London Healthcare Conference
Date:November 18, 2020 - SVB Leerink Oncology 1x1 Day
Date:November 19, 2020 - Oddo -
Tech40 Digital Forum 5th Edition
Date:November 24-25, 2020 Evercore ISI 3rd Annual HealthCONx
Date:December 1-3, 2020
Fireside Chat:December 2, 2020 at8:50-9:10 a.m. ET
A replay of Innate’s presentation at the Bryan Garnier conference and a live webcast of Innate’s presentation at the
About
Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Based in
Learn more about
Information about
ISIN code Ticker code LEI | FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in
For additional information, please contact:
Investors Tel.: +33 (0)4 30 30 30 30 investors@innate-pharma.com | Media Tel.: +1 240 801 0076 Tracy.Rossin@innate-pharma.com Marie Puvieux ( Tel.: +33 (0)9 81 87 46 72 innate-pharma@atcg-partners.com |
Source:
2020 GlobeNewswire, Inc., source